Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360) (Horizon 360)
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Prospective, Single Arm, Unblinded Pre-market Clinical Study to Evaluate the Safety and Effectiveness of the Sphere-360 Catheter and Affera Mapping and Ablation System for Treating Paroxysmal Atrial Fibrillation (PAF)
Sponsor: Medtronic Cardiac Ablation Solutions
A NA clinical study on Paroxysmal AF, this trial is actively recruiting participants. The trial is conducted by Medtronic Cardiac Ablation Solutions and has accumulated 2 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Feb 2026 — Present [monthly]
Recruiting NA
Status: Withheld → Recruiting · Phase: None → NA
-
Jan 2026 — Feb 2026 [monthly]
Withheld
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medtronic Cardiac Ablation Solutions
For direct contact, visit the study record on ClinicalTrials.gov .